Apellis Pharmaceuticals, Inc. (APLS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-14

Apellis Pharmaceuticals, Inc. (APLS) has filed 20 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-14. 2 Form 8-K material event filings were reported by APLS in the last 90 days. InsiderAlpha tracks every APLS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Apellis Pharmaceuticals, Inc. (APLS)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001492422

90-Day SEC Filing Activity

Form 4 filings (90d)	20
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-05-14

Recent APLS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-14	Watson David O.	General Counsel	J — Other acquisition / disposition	50.1K	—	—	SEC
2026-05-14	WHEELER CRAIG A	Insider	D — Derivative transaction	15.1K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	D — Derivative transaction	29.7K	—	—	SEC
2026-05-14	Watson David O.	General Counsel	J — Other acquisition / disposition	10.0K	—	—	SEC
2026-05-14	WHEELER CRAIG A	Insider	J — Other acquisition / disposition	24.4K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	A — Grant or award	26.4K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	J — Other acquisition / disposition	86.5K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	D — Derivative transaction	8.9K	—	—	SEC
2026-05-14	Watson David O.	General Counsel	J — Other acquisition / disposition	144.5K	—	—	SEC
2026-05-14	WHEELER CRAIG A	Insider	D — Derivative transaction	8.0K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	D — Derivative transaction	26.4K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	D — Derivative transaction	12.7K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	A — Grant or award	41.2K	—	—	SEC
2026-05-14	Baumal Caroline	Chief Medical Officer	D — Derivative transaction	41.2K	—	—	SEC
2026-05-14	Watson David O.	General Counsel	A — Grant or award	41.2K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Apellis Pharmaceuticals, Inc. (APLS). Updated in real time as new filings are submitted to the SEC.

Most-Active APLS Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Francois Cedric	26	—
Sullivan Timothy Eugene	25	—
Watson David O.	23	—
Deschatelets Pascal	22	—
DeLong Mark Jeffrey	21	—

Recent APLS Form 8-K Material Events

2026-05-14 — Item 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 8.01, 9.01 [SEC]
2026-05-04 — Item 5.02 [SEC]
2026-03-31 — Item 1.01, 5.02, 8.01, 9.01 · Acquisition · positive [SEC]
Apellis Pharmaceuticals entered into a definitive merger agreement with Biogen Inc., whereby Biogen will acquire all outstanding shares of Apellis for $41.00 per share in cash plus contingent value rights (CVRs) worth up to $4.00 per share based on achievement of specified milest
2026-03-02 — Item 5.02 · Leadership · neutral [SEC]
Apellis Pharmaceuticals elected Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director effective March 1, 2026. Dr. Dolsten is an independent director and will receive standard non-employee director compensation including stock options and RSUs.

Recent Insider Filings

2026-05-14 — Dunlop A. Sinclair (Insider)
2026-05-14 — Chopas James George (VP/Chief Accounting Officer)
2026-05-14 — Dolsten Mikael (Insider)
2026-05-14 — MELTZER LESLIE (Chief Research and Development)
2026-05-14 — FONTEYNE PAUL R. (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in APLS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

APLS Insider Trading — FAQ

What is the latest insider trade for APLS?: Apellis Pharmaceuticals, Inc. (APLS) had 20 insider filings in the last 90 days, with the most recent on 2026-05-14. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying APLS stock?: 0 insider purchases of APLS were filed in the last 90 days.
How many insiders are selling APLS stock?: 0 insider sales of APLS were filed in the last 90 days.
Where can I see APLS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every APLS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live APLS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.